FGF23 and hyperphosphatemia: Other models in which the phosphaturic effect of PF-06869206 has been tested are FGF23−/− mice (characterized by growth retardation, abnormal bone phenotype, hyperphosphatemia and short life span [46]) and GALNT3−/− mice (characterized by increased FGF23 proteolysis consequently lowering intact FGF23 levels and leading to hyperphosphatemic familial tumoral calcinosis [47]).